Stacy Loeb1, Hans Lilja, Andrew Vickers. 1. aDepartment of Urology bDepartment of Population Health, New York University cDepartment of Laboratory Medicine dDepartment of Surgery eDepartment of Medicine fDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA gNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK hDepartment of Translational Medicine, Lund University, Malmö, Sweden.
Abstract
PURPOSE OF REVIEW: The purpose of this article is to review blood and urine tests that are currently available and under investigation for a role in prostate cancer screening and detection. RECENT FINDINGS: Compared with total prostate-specific antigen (PSA) alone, its combination with percentage free-to-total PSA contributes greater specificity for prostate cancer, and is a component of two newer blood tests called the 4kScore and Prostate Health Index. All three tests improve the prediction of high-grade disease and are commercially available options to aid in initial or repeat prostate biopsy decisions. PCA3 is a urinary marker that is currently available for repeat prostate biopsy decisions. Although PCA3 alone has inferior prediction of clinically significant disease and requires collection of urine after digital rectal examination, it may be combined with other clinical variables or other urine markers like TMPRSS2:ERG to improve performance. Little data are available to support a role for single nucleotide polymorphisms or other investigational markers in early detection. SUMMARY: Several commercially available blood and urine tests have been shown to improve specificity of PSA for high-grade prostate cancer. Use of such tests would decrease unnecessary biopsy and overdiagnosis of indolent disease. Biopsy of men with moderately elevated PSA without use of such a reflex test should be discouraged.
PURPOSE OF REVIEW: The purpose of this article is to review blood and urine tests that are currently available and under investigation for a role in prostate cancer screening and detection. RECENT FINDINGS: Compared with total prostate-specific antigen (PSA) alone, its combination with percentage free-to-total PSA contributes greater specificity for prostate cancer, and is a component of two newer blood tests called the 4kScore and Prostate Health Index. All three tests improve the prediction of high-grade disease and are commercially available options to aid in initial or repeat prostate biopsy decisions. PCA3 is a urinary marker that is currently available for repeat prostate biopsy decisions. Although PCA3 alone has inferior prediction of clinically significant disease and requires collection of urine after digital rectal examination, it may be combined with other clinical variables or other urine markers like TMPRSS2:ERG to improve performance. Little data are available to support a role for single nucleotide polymorphisms or other investigational markers in early detection. SUMMARY: Several commercially available blood and urine tests have been shown to improve specificity of PSA for high-grade prostate cancer. Use of such tests would decrease unnecessary biopsy and overdiagnosis of indolent disease. Biopsy of men with moderately elevated PSA without use of such a reflex test should be discouraged.
Authors: Andrew J Vickers; Angel M Cronin; Gunnar Aus; Carl-Gustav Pihl; Charlotte Becker; Kim Pettersson; Peter T Scardino; Jonas Hugosson; Hans Lilja Journal: Cancer Date: 2010-06-01 Impact factor: 6.860
Authors: Xiaoju Wang; Jianjun Yu; Arun Sreekumar; Sooryanarayana Varambally; Ronglai Shen; Donald Giacherio; Rohit Mehra; James E Montie; Kenneth J Pienta; Martin G Sanda; Philip W Kantoff; Mark A Rubin; John T Wei; Debashis Ghosh; Arul M Chinnaiyan Journal: N Engl J Med Date: 2005-09-22 Impact factor: 91.245
Authors: Arun Sreekumar; Laila M Poisson; Thekkelnaycke M Rajendiran; Amjad P Khan; Qi Cao; Jindan Yu; Bharathi Laxman; Rohit Mehra; Robert J Lonigro; Yong Li; Mukesh K Nyati; Aarif Ahsan; Shanker Kalyana-Sundaram; Bo Han; Xuhong Cao; Jaeman Byun; Gilbert S Omenn; Debashis Ghosh; Subramaniam Pennathur; Danny C Alexander; Alvin Berger; Jeffrey R Shuster; John T Wei; Sooryanarayana Varambally; Christopher Beecher; Arul M Chinnaiyan Journal: Nature Date: 2009-02-12 Impact factor: 49.962
Authors: Massimo Lazzeri; Alexander Haese; Alexandre de la Taille; Joan Palou Redorta; Thomas McNicholas; Giovanni Lughezzani; Vincenzo Scattoni; Vittorio Bini; Massimo Freschi; Amy Sussman; Bijan Ghaleh; Philippe Le Corvoisier; Josep Alberola Bou; Salvador Esquena Fernández; Markus Graefen; Giorgio Guazzoni Journal: Eur Urol Date: 2013-01-24 Impact factor: 20.096
Authors: Hardev Pandha; Karen D Sorensen; Thorsten F Orntoft; Stephen Langley; Soren Hoyer; Michael Borre; Richard Morgan Journal: BJU Int Date: 2012-05-15 Impact factor: 5.588
Authors: Claire de la Calle; Dattatraya Patil; John T Wei; Douglas S Scherr; Lori Sokoll; Daniel W Chan; Javed Siddiqui; Juan Miguel Mosquera; Mark A Rubin; Martin G Sanda Journal: J Urol Date: 2015-01-28 Impact factor: 7.450
Authors: Andrew J Vickers; Angel M Cronin; Gunnar Aus; Carl-Gustav Pihl; Charlotte Becker; Kim Pettersson; Peter T Scardino; Jonas Hugosson; Hans Lilja Journal: BMC Med Date: 2008-07-08 Impact factor: 8.775
Authors: Enrique Gomez Gomez; Juan José Salamanca Bustos; Julia Carrasco Valiente; Jose Luis Fernandez Rueda; Ana Blanca; José Valero Rosa; Ines Bravo Arrebola; Javier Marquez López; Juan Manuel Jimenez Vacas; Raul Luque; Maria José Requena Tapia Journal: BMJ Open Date: 2019-11-12 Impact factor: 2.692
Authors: Enrique Gómez-Gómez; Juan M Jiménez-Vacas; Julia Carrasco-Valiente; Vicente Herrero-Aguayo; Ana M Blanca-Pedregosa; Antonio J León-González; José Valero-Rosa; José L Fernández-Rueda; Teresa González-Serrano; José López-Miranda; Manuel D Gahete; Justo P Castaño; María J Requena-Tapia; Raúl M Luque Journal: J Cell Mol Med Date: 2018-09-06 Impact factor: 5.310